Sun Pharma Advances Potential Treatment for Alopecia Areata with Deuruxolitinib NDA Acceptance by US FDA

6 Oct 2023 , 03:34 PM

Sun Pharmaceutical Industries announces US FDA acceptance of deuruxolitinib new drug application for alopecia areata treatment. The investigational oral drug is intended for adults with moderate to severe alopecia areata.

Sun Pharma submits 8mg twice daily regimen of deuruxolitinib for USFDA review in the new drug application. The potential of deuruxolitinib as a crucial treatment option emphasized by Sun Pharma CEO for those dealing with chronic alopecia areata.

NDA for deuruxolitinib based on comprehensive Phase III trials involving 1,200+ patients across 135+ clinical trial sites. Recent data from these trials presented at major dermatology meetings, showcasing the drug’s potential effectiveness.

For feedback and suggestions, write to us at [e-mail]